RxDoctor Payments Data

Thomas Callahan, DO

Family Medicine · Phoenix, AZNPI 1164861027

Payments from drug & device makers

$11,108in general payments, 2019–2025

Across 554 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • AbbVie$2K
  • AstraZeneca$759
  • Lilly USA, LLC$720
  • Novartis$584
  • Pfizer$537
  • plus $4K from 44 others

What the payments were for

  • Travel & lodging$2,97427%
  • Food & beverage$8,12373%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,108 in reported general payments places this provider in the 90th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$173,598
Medicare patients
498
Services billed
2,894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$119,406
JardianceEmpagliflozin74$116,108
EliquisApixaban117$112,029
XareltoRivaroxaban73$68,221
MyrbetriqMirabegron72$66,894
TrulicityDulaglutide55$60,697
ViberziEluxadoline20$41,256
MounjaroTirzepatide25$32,137
Repatha SureclickEvolocumab29$29,154
Synjardy XrEmpagliflozin/Metformin Hcl12$19,307
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$15,067
MovantikNaloxegol Oxalate26$10,616
RybelsusSemaglutide11$10,530
PremarinEstrogens, Conjugated19$10,284
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$135$135,41586 claims
Novo NordiskOzempic, Rybelsus$396$129,93682 claims
PfizerEliquis, Premarin$537$122,313136 claims
Lilly USA, LLCTrulicity, Mounjaro$720$92,83480 claims
Johnson & JohnsonXarelto$371$68,22173 claims
Astellas Pharma US IncMyrbetriq$12$66,89472 claims
AbbVieViberzi, Synthroid$1,578$44,20961 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$105$24,83849 claims
AstraZenecaBreztri Aerosphere, Symbicort$759$14,58425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →